Forward Pharma A/S (NASDAQ:FWP) has received a consensus recommendation of “Buy” from the six analysts that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation, two have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $24.00.

A number of research firms have weighed in on FWP. BidaskClub raised shares of Forward Pharma A/S from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 30th. ValuEngine raised shares of Forward Pharma A/S from a “sell” rating to a “hold” rating in a report on Saturday, June 17th.

Several large investors have recently bought and sold shares of the company. OxFORD Asset Management LLP bought a new stake in shares of Forward Pharma A/S in the 2nd quarter valued at $210,000. Senzar Asset Management LLC boosted its stake in shares of Forward Pharma A/S by 38.2% in the 2nd quarter. Senzar Asset Management LLC now owns 652,500 shares of the biotechnology company’s stock valued at $13,265,000 after purchasing an additional 180,200 shares during the last quarter. BlueMountain Capital Management LLC boosted its stake in shares of Forward Pharma A/S by 15.3% in the 2nd quarter. BlueMountain Capital Management LLC now owns 1,511,043 shares of the biotechnology company’s stock valued at $26,982,000 after purchasing an additional 200,000 shares during the last quarter. Cowen Inc. bought a new stake in shares of Forward Pharma A/S in the 2nd quarter valued at $225,000. Finally, Alliancebernstein L.P. bought a new stake in shares of Forward Pharma A/S in the 2nd quarter valued at $203,000. 21.85% of the stock is currently owned by institutional investors.

Forward Pharma A/S (NASDAQ FWP) traded down 0.7773% during midday trading on Tuesday, reaching $28.0304. 23,000 shares of the company’s stock traded hands. Forward Pharma A/S has a 1-year low of $14.89 and a 1-year high of $33.00. The firm’s market cap is $1.32 billion. The stock’s 50 day moving average price is $24.51 and its 200 day moving average price is $22.75.

The company also recently disclosed an annual dividend, which will be paid on Monday, September 11th. Stockholders of record on Thursday, September 7th will be paid a $22.903 dividend. The ex-dividend date is Wednesday, September 6th.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of international trademark and copyright law. The original version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/08/forward-pharma-as-fwp-receives-24-00-consensus-target-price-from-analysts.html.

About Forward Pharma A/S

Forward Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in the development of FP187, a formulation of dimethyl fumarate (DMF) for the treatment of several inflammatory and neurological indications, including multiple sclerosis (MS). The Company’s clinical candidate, FP187, is under development for the treatment of relapsing remitting MS (RRMS) and other immune disorders, such as psoriasis.

Receive News & Stock Ratings for Forward Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Forward Pharma A/S and related stocks with our FREE daily email newsletter.